Tag: CLTI
Deep vein arterialisation: “A real advance” for treatment of ‘no-option’ CLTI
Daniel Clair (Vanderbilt University Medical Center, Nashville, USA) speaks to Vascular News at this year’s VEITHsymposium (14–18 November, New York, USA) on deep vein...
Inari Medical completes LimFlow acquisition for CLTI treatment
Inari Medical has announced that it has completed its acquisition of chronic limb-threatening ischaemia (CLTI) treatment maker LimFlow.
The Irvine, California–based company earlier this month...
“First victory” in BTK space demonstrates lessons learned and paves the...
Lawrence Garcia (St Francis Hospital, New York, USA) speaks to Vascular News at VIVA 2023 (30 October–2 November, Las Vegas, USA) on lessons learned...
Two-year SWING data “continue to show promise” for sirolimus DCB in...
Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been...
Revascularisation considered over amputation for CLTI in UK, new study states
A new study published in BJS Open has found that revascularisation treatment to restore blood flow to the legs of patients with severely blocked arteries is...
PROMISE II 12-month data show durable outcomes with the LimFlow system...
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the...
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical.
A press release details that, under the terms...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough...
Results of the LIFE-BTK randomised controlled trial have just been presented at TCT 2023 (23–26 October, San Francisco, USA). The data show that, in...
Vascular News’ top 10 most popular stories of September 2023
Discussions on the role of aritifical intelligence in the vascular field and emerging deep venous valve technologies caught readers' attention in September.
1. Humacyte announces...
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in...
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening...
US FDA approves LimFlow system for treatment of CLTI
The US Food and Drug Administration (FDA) today announced approval of LimFlow therapy—a novel and minimally invasive procedure designed to bypass blockages in arteries...
SVS responds to New York Times article on overuse of vascular...
In an official Society response, SVS president Joseph Mills tackles recent coverage in the mainstream media of inappropriateness in vascular care.
There have been several...
BEST-CLI investigators implore a move beyond endo versus open “battle” in...
The principal investigators behind the BEST-CLI trial struck a conciliatory tone during the inaugural Frank J Veith Distinguished Lecture at this year’s Society for...
Connect the world session at LINC 2023 projects “outstanding” first-release data...
The Connect The World Session: Japan at this year’s Leipzig Interventional Course (LINC 2023, 6–9 June, Leipzig, Germany)—in collaboration with the Japanese Endovascular...
Study finds Serranator serration balloon safe and effective in pedal arteries
A recent study has concluded that the “novel” technique of serration angioplasty with the Serranator balloon (Cagent Vascular) for the treatment of chronic limb-threatening...
Urban residents have smaller risk of mortality from chronic limb-threatening ischaemia
A new study using data from millions of patients hospitalised across the USA has determined whether population density and associated urban versus suburban versus...
Insights from largest chronic limb-threatening ischaemia study to inform quality of...
Data from a cohort of one million patients with chronic limb-threatening ischaemia (CLTI) were recently presented as late-breaking clinical research at the Society for Cardiovascular...
New analysis of chronic limb-threatening ischaemia patients places BEST-CLI trial into...
A new analysis of chronic limb-threatening ischaemia (CLTI) treatment outcomes was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography &...
BASIL-2 points towards endovascular-first revascularisation strategy in CLTI patients
A question from Manj Gohel (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) on what the Charing Cross (CX) audience should take back to...
Vascular News’ top 10 most popular stories of March 2023
The US launch of a new peripheral intravascular lithotripsy (IVL) catheter, new data on large bore mechanical thrombectomy in high-risk pulmonary embolism (PE) patients,...
ESRD strongly associated with adverse limb events in new study
A new investigation into the association between end-stage renal disease (ESRD) and major adverse limb events (MALEs) has found that not only is it...
“Save a limb, save a life”
“When you save a limb, you save a life” Marianne Brodmann (Graz, Austria) tells CX Live. There are many people who never get seen...
Results from PROMISE II pivotal trial suggest “transformational value” of deep...
Results from the PROMISE II pivotal trial investigating transcatheter arterialisation of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischaemia...
CX 2023 highlight: The BASIL-2 trial
Data and discussion on revascularisation treatment strategies for patients with chronic limb-threatening ischaemia (CLTI) will take centre stage at the CX 2023 Consensus update,...
Cost effectiveness of urea-based DCB treatment for CLTI patients “extremely important”
A range of experts, including Koen Deloose (Dendermonde, Belgium), Thomas Zeller (Bad Krozingen, Germany), Marianne Brodmann (Graz, Austria) and Antonio Micari (Messina, Italy), talk...
Shockwave IVL: Improving compliance is the key to “best endovascular” CFA...
This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here.
In this case report, Narayanan...
Shockwave IVL: Preserving options in no-stent zones
This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here.
Bella Huasen (Lancashire Teaching Hospitals...
BioGenCell begins recruitment for clinical trial of stem cell-based treatment for...
BioGenCell has announced that it is recruiting for an international clinical trial to assess the company's stem cell-based therapy for chronic limb-threatening ischaemia patients...
Jon Boyle
Following his 2021–2022 presidency of the Vascular Society of Great Britain and Ireland (VSGBI), Jon Boyle (Cambridge University Hospitals NHS Trust, Cambridge, UK) speaks...
UK NVR annual report highlights “extremely high” case ascertainment rates despite...
The UK National Vascular Registry (NVR) recently published its 2022 annual report—the 10th since the registry was launched in 2013—highlighting important outcome data for...
“A very grey area”: EVOCC trial addresses best treatment option for...
Athanasios Saratzis (University of Leicester, Leicester, UK) speaks to Vascular News about the EVOCC trial, which he hopes will dispel patient and physician “uncertainty”...
Vascular News’ top 10 most popular stories of November 2022
November's top 10 includes the first results from BEST-CLI, as well as new data presented at this year's Vascular Interventional Advances (VIVA; 31 October–3...
VSGBI President’s Symposium spotlights data-driven financial incentives for PAD revascularisation
The President’s Symposium at the Vascular Society of Great Britain and Ireland (VSGBI) annual scientific meeting (23–25 November, Brighton, UK) featured Rob Sayers’ (University...
SWING trial 12-month data: Novel sirolimus DCB shows “great promise” in...
The Sundance (Surmodics) sirolimus drug-coated balloon (DCB) has an “excellent” safety profile in a “challenging, real-world, predominantly CLTI population,” and has a primary...
First data from BEST-CLI bring surgical bypass into the forefront of...
The first results from the BEST-CLI randomised controlled trial (RCT) of 1,830 patients show that surgical bypass with adequate single-segment great saphenous vein (GSV)...
BEST-CLI attracts US$3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a US$3.3 million contribution toward the BEST-CLI (Best endovascular versus best surgical therapy in patients with critical limb...
First US patient enrolled in Selution SLR IDE peripheral study
The first US patient has been enrolled in the US Food and Drug Administration (FDA) SELUTION4BTK (below-the-knee) clinical trial evaluating Selution SLR, MedAlliance's novel...
First patients enrolled in LIMES randomised trial of Magic Touch sirolimus-coated...
Concept Medical has announced the initiation of the LIMES trial, which has enrolled 15 patients to evaluate the safety and efficacy of the company's...
Researchers report higher three-year amputation and reintervention rates in Black and...
In a study of over 7,000 chronic limb-threatening ischaemia (CLTI) patients, researchers found that Black and Hispanic patients had higher three-year amputation and reintervention...
Philips announces positive three-year clinical research results from its TOBA II...
Royal Philips today announced the latest results from the Tack optimised balloon angioplasty (TOBA) II below-the-knee (BTK) clinical trial, demonstrating that the Philips endovascular...
Revascularisation strategy for BTK intervention should hinge on diagnostic modality, LINC...
New data provide “another argument” for the use of intravascular ultrasound (IVUS) in below-the-knee (BTK) interventions. This is according to Michael Lichtenberg (Arnsberg Vascular...
Non-optimal therapy for CLTI “more prominent in females”
A real-world claims data analysis of nearly 200,000 patients with chronic limb-threatening ischaemia (CLTI) showed that female patients were older, underwent vascular procedures less...
SCAI releases multi-society position statement focused on core competencies for endovascular...
The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement outlining competencies for endovascular specialists who provide care for chronic limb-threatening...
LimFlow raises US$40 million in Series D financing
LimFlow recently announced it has closed a US$40 million (€36 million) oversubscribed Series D financing round.
A press release reports that new investors Longitude...
PROMISE II US pivotal trial of device designed for “no-option” CLTI...
Enrolment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialisation system (LimFlow SA) designed to prevent amputations in...
CX 2022 highlights new data in the vascular world
Anticipation is building for the Charing Cross International Symposium 2022 (26–28 April, London, UK, in person and virtual), which this year will address some...
Vascular News’ top 10 most popular stories of January 2022
Breakthrough designation for a new drug-eluting stent from Cook Medical, a meta-analysis on the safety of expedited carotid artery surgery vs. expedited stenting after...
Humacyte’s Human Acellular Vessel for limb salvage evaluated in multiple complex...
Humacyte today announced results from the first series of compassionate use cases of the company’s investigational Human Acellular Vessel (HAV) for the treatment of...
Cook Medical receives FDA breakthrough designation for new drug-eluting stent
Cook Medical has received Breakthrough Device designation from the US Food and Drug Administration (FDA) on a new drug-eluting stent for below the knee...
Novel system-wide interdisciplinary team diverts patients from amputation and improves outcomes
Findings from a first-of-its-kind study conducted at University Hospitals (UH) Harrington Heart & Vascular Institute (Cleveland, USA) showed a novel system-wide interdisciplinary team assembled...
Cordis names George Adams as chief medical officer
Cordis has announced George Adams as chief medical officer.
"We are delighted to have Dr Adams join our team as we continue to build the...
Shockwave Medical enrols first patient in Disrupt BTK II study for...
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the...
Vascular News’ top 10 most popular stories of October 2021
New data from a head-to-head, randomised trial comparing vascular closure devices, highlights from CX Aortic Vienna 2021 (5–7 October, broadcast) and an interview with past Society...
FDA clears 12 new XO Cross microcatheters
Transit Scientific has announced US Food and Drug Administration (FDA) clearance of new hydrophilic-coated XO Cross microcatheters for guidewire support, exchange, and contrast media...
Surgeons must stay skilled in femorotibial/pedal bypass surgery, PVI audience hears
At Paris Vascular Insights (PVI) 2021 (21–23 October, Paris, France), Peter Schneider (University of California San Francisco, San Francisco, USA) emphasised the need for...
Study supports use of WIfI classification system to predict revascularisation benefit...
A retrospective study supports the use of the Wound, ischaemia, and foot infection (WIfI) classification system to predict the revascularisation benefit for diabetic patients...
VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...
Why Rotarex is my first choice treatment in patients with bypass...
NOTE: This video is ONLY available to watch in selected countries and geographies
Bruno Migliara (Peschiera del Garda, Italy) talks to Vascular News about the reasons...
R3 Vascular reports the initiation of its first-in-human clinical study
R3 Vascular has reported the successful initiation of its first-in-human clinical study evaluating the technical and clinical performance of the R3 Vascular Magnitude bioresorbable...
PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrolment
MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of...
PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrolment
MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of...
Vascular News’ top 10 most popular stories of June 2021
New data from Philips' TOBA II below-the-knee (BTK) clinical trial, physicians' call for the AMPREDICT decision support tool to be applied in clinical practice,...
Lack of access to vascular specialists creates major disparities in amputation...
Speaking on current trends in amputation rates with critical limb-threatening ischaemia (CLTI) patients, Misty Humphries (Sacramento, USA) tells Vascular News that while Medicare data shows that amputation rates...
Physicians call for clinical application of “helpful, meaningful” AMPREDICT decision support...
Researchers have found that the AMPREDICT decision support tool (DST) demonstrates “strong usability characteristics and clinical relevance” in amputation level decision-making for patients with...
Vascular News’ top 10 most popular stories of May 2021
Expanding eligibility for endovascular aneurysm repair (EVAR), new tools for chronic limb-threatening ischaemia (CLTI), and promising data for arteriovenous (AV) fistula remote monitoring all...
SoundBite Medical announces use of its Active Wire 0.014″ platform at...
SoundBite Medical Solutions recently announced the use of its novel Active Wire 0.014” platform at a first site in the USA in the successful...
XO Score scoring sheath platform wins medical design award
Transit Scientific today announced that its XO Score scoring sheath platform has been named a winner in the 2021 Medical Design Excellence Awards (MDEA)....
One-year outcomes from PROMISE I US study of LimFlow system published
LimFlow SA recently announced the publication of 12-month data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
One-year outcomes from PROMISE I US study of LimFlow system published
LimFlow SA recently announced the publication of 12-month data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
New tools for CLTI: ISET audience hear what’s on the horizon...
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco,...
New tools for CLTI: ISET audience hear what’s on the horizon...
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco,...
Micro Medical Solutions receives FDA breakthrough device designation for MicroStent vascular...
Micro Medical Solutions (MMS) recently announced that the US Food and Drug Administration (FDA) has granted breakthrough device designation for its MicroStent vascular stent....
Micro Medical Solutions receives FDA breakthrough device designation for MicroStent vascular...
Micro Medical Solutions (MMS) recently announced that the US Food and Drug Administration (FDA) has granted breakthrough device designation for its MicroStent vascular stent....
“A reliable tool”: Positive findings for 2D perfusion angiography in CLTI...
Researchers suggest that in patients with chronic limb-threatening ischaemia (CLTI), two-dimensional (2D) perfusion angiography is a “reliable tool” when used according to standardised methods....
Introduction of dedicated vascular limb salvage clinic improves one-year amputation outcomes...
One-year outcomes of patients with chronic-limb threatening ischaemia (CLTI) treated in an outpatient-based vascular limb salvage clinic show an improved rate of major amputation....
Novel PAD treatment may be more cost-effective than standard care, study...
FlowOx therapy (Otivio) delivered as a single annual dose may be a cost-effective treatment for peripheral arterial disease (PAD), a recent study published in...
The CLI Global Society announces the Journal of Critical Limb Ischemia
The CLI Global Society is launching the first peer-reviewed academic journal focusing on interventional techniques pertaining to critical limb ischemia (CLI). The new journal,...
The CLI Global Society announces the Journal of Critical Limb Ischemia
The CLI Global Society is launching the first peer-reviewed academic journal focusing on interventional techniques pertaining to critical limb ischemia (CLI). The new journal,...
Real-world data on SeQuent Please OTW DCB presented at LINC 2021
One-year findings of the CONSEQUENT all-comers observational study of the paclitaxel drug-coated balloon (DCB) SeQuent Please OTW (B Braun) were reported at LINC 2021...
LINC 2021: New data show potential of Limflow system to improve...
In a late-breaking trial session at LINC 2021 (The Leipzig Interventional Course, 25–29 January, online), key updates on below-the-knee (BTK) interventions were in the spotlight. Speaking during his...
FDA grants breakthrough device designation to PEDRA Xauron real-time tissue perfusion...
The US Food and Drug Administration (FDA) has granted Pedra Technology a breakthrough device designation for the periprocedural use of the company’s Pedra Xauron...
FDA grants breakthrough device designation to PEDRA Xauron real-time tissue perfusion...
The US Food and Drug Administration (FDA) has granted Pedra Technology a breakthrough device designation for the periprocedural use of the company’s Pedra Xauron...
No safety concerns and favourable patency at two years with Absorb...
The Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) can be used for the treatment of chronic limb-threatening ischaemia (CLTI) patients in infrapopliteal arteries with...
CDC recognises and codifies critical limb-threatening ischaemia in ICD-10-CM
A coalition organised by the CLI Global Society has announced its proposal to distinctly recognise "critical limb ischaemia" (CLI) and "chronic limb-threatening ischaemia" (CLTI)...
CDC recognises and codifies critical limb-threatening ischaemia in ICD-10-CM
A coalition organised by the CLI Global Society has announced its proposal to distinctly recognise "critical limb ischaemia" (CLI) and "chronic limb-threatening ischaemia" (CLTI)...
Deep vein arterialisation should be considered in “no option” CLTI patients,...
Midterm results from a study of the largest population of patients with no-option chronic limb-threatening ischaemia (CLTI) treated with percutaneous deep vein arterialisation (pDVA)...
“Rapid reduction” in amputations follows opening of multidisciplinary limb preservation service
A multidisciplinary limb preservation service under the leadership of vascular surgery in a level one trauma centre was associated with an immediate and rapid...
Systematic review and meta-analysis finds “substantial” one-year mortality rate in octogenarians...
In octogenarians with chronic limb-threatening ischaemia (CLTI), researchers found a one-year mortality rate of 32% after revascularisation, which was significantly higher than in non-octogenarians....
MERLION trial six-month outcomes presented at VIVA late-breaking trial session
Six-month clinical outcomes of the MERLION trial were presented as part of the VIVA Late-Breaking Clinical Trials Livesteam (25 June), by Tjun Tang (Singapore...
“On the descending curve”: BEST-CLI rises to COVID-19 and financial challenges
Vascular News spoke to the principal investigators of the BEST-CLI (Best endovascular versus best surgical therapy in critical limb ischaemia) trial—Alik Farber (Boston Medical...
Rexgenero acquires the key technology and programme assets of aratinga.bio SAS...
Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLTI), has announced the acquisition of all the key assets...
Pedal artery revascularisation: Is it ready for prime time?
Reviewing the available evidence for below-the-ankle interventions in the treatment of critical limb-threatening ischaemia (CLTI), Srini Tummala proposes that pedal artery intervention “should be...
Letter from Seattle: Amid COVID-19 pandemic, time to act is long...
Amid the COVID-19 pandemic, Benjamin W Starnes and Niten Singh urge service chiefs across the USA to "act this minute" in order to conserve...
Interdisciplinary wound care teams are integral for CLTI patients’ care, ISET...
The 32nd International Symposium on Endovascular Therapy (ISET; 22–25 January, Hollywood, USA) had a particular focus on treating critical limb-threatening ischaemia (CLTI). In the...
Interdisciplinary wound care teams are integral for CLTI patients’ care, ISET...
The 32nd International Symposium on Endovascular Therapy (ISET; 22–25 January, Hollywood, USA) had a particular focus on treating critical limb-threatening ischaemia (CLTI). In the...
New meta-analysis finds “no observed difference” in mortality between paclitaxel and...
February 2020 brings another paclitaxel device meta-analysis of randomised controlled trials in chronic limb-threatening ischaemia (CLTI) patients. Krystal Dinh (Westmead Hospital, Sydney, Australia) et...
Vascular surgeons and cardiologists respond to new meta-analysis of PCBs in...
Eminent vascular surgeons and interventional cardiologists including Kim Hodgson (Springfield, USA), Ramon Varcoe (Sydney, Australia) and Gary Ansel (Columbus, USA) give their thoughts on...
IR experts respond to new meta-analysis of paclitaxel-coated balloons in infrapopliteal...
A range of interventional radiology experts including Michael Dake (Tucson, USA), John Kaufman (Portland, USA), Jim Reekers (Amsterdam, The Netherlands) and Gunnar Tepe (Rosenheim,...
Global vascular guidelines for CLTI are gaining traction but work remains...
The application of new global vascular guidelines for chronic limb-threatening ischaemia (CLTI) provides an opportune and worthwhile window to revisit the concept of critical...
Vascular limb salvage (VaLS) clinic helps to meet the VSGBI time-to-treatment...
Described as “deliberately challenging”, the new time-to-treatment targets published by the Vascular Society of Great Britain and Ireland (VSGBI), as part of the Peripheral...
First CLTI patient enrolled in PROMISE II pivotal study of LimFlow...
LimFlow, a specialist in minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced...
LimFlow receives FDA approval for US study of minimally-invasive technology designed...
LimFlow has announced that the US Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) for the PROMISE II pivotal study of...
LimFlow receives FDA approval for US study of minimally-invasive technology designed...
LimFlow has announced that the US Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) for the PROMISE II pivotal study of...
New Global Vascular Guidelines for CLTI patients now open for stakeholder...
The draft Global Vascular Guidelines on chronic limb threatening ischaemia (CLTI) have just been posted for open public comment until 3 December 2018. Michael...
